Drug Search Results
More Filters [+]

ODM-102

Alternative Names: odm-102, odm102, odm 102
Latest Update: 2014-02-10
Latest Update Note: Clinical Trial Update

Product Description

alpha-2c adrenoceptor antagonist (Sourced from: https://www.orion.fi/en/Orion-group/media/stock-exchange-releases/2014/orion-group-financial-statement-release-for-2013/)

Mechanisms of Action: ADRA2C Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Orion Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ODM-102

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01839019

P1

Completed

Healthy Volunteers

2013-06-01

Recent News Events

Date

Type

Title